EIP (2024) Crosswalk of Changes (24BX)

Cross walk - 2024 form changes

ABCs

1. ABCs Case Report Form - Attachment #3
   
   
   

	2023 Form	2024 Form (Changes in yellow highlight)
a)		Appended to County (Patient Residence): 6a. Planning Region

2. ABCs Invasive Pneumococcal Disease (IPD) Report Form - Attachment #4
   
   
   

	2023 Form	2024 Form (Changes in yellow highlight)
a)		Updated overall design of the form to show available all data value sets.
b)		Addition of unknown checkboxes for all vaccination date variables.
c)		Removed questions.

FoodNET

1. FoodNet Active Surveillance Data Elements List – Attachment #5

Variable #2 AgClinicTestType – Added Meridian Curian Campy to Value Set. See highlighted in Yellow.

Variable #6 AgSphlTestType – Added Meridian Curian Campy to Value Set. See highlighted in Yellow.

The following 3 data elements questions the word “isolate” was inserted for better clarification highlighted in Yellow below:

1. StecHAg – Variable #121

   1. If E. coli, what was the H-antigen number for the isolate?

2. StecOAg – Variable #122

   1. If E. coli, what was the O-antigen number for the isolate?

3. StecStx – Variable #123

   1. Was E. coli isolate Shiga toxin-producing?

FluSurv-Net

1. FluSurv-NET Influenza Surveillance Project Case Report Form– Attachment #6

Question on 2022-23 Form	Questions on 2023-24 Form
Case Classification □ Prospective □ Surveillance Discharge Audit	Case Classification □ Surveillance Discharge Audit
C15. Where did the patient reside at the time of hospitalization (Indicate type of residence) Private residence Private residence with services Homeless/Shelter Nursing home/Skilled nursing facility Alcohol/Drug Abuse Treatment Hospitalized at birth Rehabilitation facility Corrections facility Hospice Assisted living/Residential care LTACH Group/Retirement home Psychiatric facility Other long term care facility Other, specify:_______ Unknown	C15. Where did the patient reside at the time of hospitalization (Indicate type of residence) Private residence Private residence with services Homeless/Shelter/Temporary housing Nursing home/Skilled nursing facility Substance abuse treatment center Hospitalized at birth Rehabilitation facility Corrections facility Hospice Assisted living/Residential care LTACH Group/Retirement home Psychiatric facility Other long term care facility Other, specify:_______ Unknown
F2. If patient discharged alive, please indicate to where: Private residence Private residence with services Homeless/Shelter Nursing home/Skilled nursing facility Alcohol/Drug Abuse Treatment Hospitalized at birth Rehabilitation facility Corrections facility Hospice Assisted living/Residential care LTACH Group/Retirement home Psychiatric facility Other long term care facility Against medical advice (AMA) Discharged to another hospital Other, specify:_______ Unknown	F2. If patient discharged alive, please indicate to where: Private residence Private residence with services Homeless/Shelter/Temporary housing Nursing home/Skilled nursing facility Substance abuse treatment center Hospitalized at birth Rehabilitation facility Corrections facility Hospice Assisted living/Residential care LTACH Group/Retirement home Psychiatric facility Other long term care facility Against medical advice (AMA) Discharged to another hospital Other, specify:_______ Unknown
G1. Reason for admission: “Influenza/COVID/RSV-related illness” OB/Labor and delivery admission Inpatient surgery procedures Psychiatric admission needing acute medical care Trauma Unknown Other, specify: _________	G1. Reason for admission: “Influenza/COVID/RSV-related illness” OB/Labor and delivery admission Inpatient surgery procedures Psychiatric admission needing acute medical care Trauma Newborn/Hospitalized at birth Unknown Other, specify: _________
G2. Acute signs/symptoms present at admission (began or worsened within 2 weeks prior to admission) (Select all that apply) Non respiratory symptoms Abdominal pain Altered mental status/confusion Anosmia/decreased smell Chest pain Conjunctivitis Diarrhea Dysgeusia/decreased taste Fatigue Fever/chills Headache Muscle aches/myalgias Nausea/vomiting Rash Seizures	G2. Acute signs/symptoms present at admission (began or worsened within 2 weeks prior to admission) (Select all that apply) Non respiratory symptoms Abdominal pain Altered mental status/confusion Anosmia/decreased smell Chest pain/tightness Conjunctivitis Diarrhea Dysgeusia/decreased taste Fatigue Fever/chills Headache Muscle aches/myalgias Nausea/vomiting Rash Seizures
G2. Acute signs/symptoms present at admission (began or worsened within 2 weeks prior to admission) (Select all that apply) Respiratory symptoms Congested/runny nose Cough Hemoptysis/bloody sputum Shortness of breath/respiratory distress Sore throat URI/ILI Wheezing	G2. Acute signs/symptoms present at admission (began or worsened within 2 weeks prior to admission) (Select all that apply) Respiratory symptoms Congested/runny nose Chest congestion Cough Hemoptysis/bloody sputum Shortness of breath/respiratory distress Sore throat URI/ILI Wheezing
G2. Acute signs/symptoms present at admission (began or worsened within 2 weeks prior to admission) (Select all that apply) For cases <2 years Apnea Cyanosis Decreased vocalization/stridor Dehydration Hypothermia Inability to eat/poor feeding Lethargy	G2. Acute signs/symptoms present at admission (began or worsened within 2 weeks prior to admission) (Select all that apply) For cases <12 years Apnea Cyanosis Stridor/decreased vocalization Dehydration/decreased urine output Hypothermia Inability to eat/poor feeding Irritability/fussiness/excess crying Lethargy/decreased activity Nasal flaring/grunting/retractions Tachypnea/increased work of breathing
I1a. If yes, what is the specimen source? Blood Bronchoalveolar lavage (BAL) Pleural fluid Cerebrospinal fluid (CSF) Sputum Endotrache aspirate Other, specify: ___________	I1a. If yes, what is the specimen source? Blood Bone/joint aspirate Bronchoalveolar lavage (BAL), bronchial aspirate/wash Cerebrospinal fluid (CSF) Endotracheal/tracheal aspirate Peritoneal or abdominal fluid/ascites Pleural fluid Sputum Wound- Group A Streptococcus (only) Other, specify: ___________
J1. Was patient tested for any of the following viral respiratory pathogens within 14 days prior to admission or ≤3 days after admission? RSV Adenovirus Parainfluenza 1 Parainfluenza 2 Parainfluenza 3 Parainfluenza 4 Human metapneumovirus Rhinovirus/Enterovirus Coronavirus SARS-CoV-2 Coronavirus, other	J1. Was patient tested for any of the following viral respiratory pathogens within 14 days prior to admission or ≤3 days after admission? RSV Adenovirus Parainfluenza 1 Parainfluenza 2 Parainfluenza 3 Parainfluenza 4 Human metapneumovirus Rhinovirus/Enterovirus Coronavirus 229E Coronavirus HKU1 Coronavirus NL63 Coronavirus OC43 Coronavirus SARS-CoV-2 Coronavirus (not further specified)
L. Chest Imaging – Based on radiology report only 2b. For the first abnormal chest x-ray, please check all that apply Report not available Air space density Air space opacity Bronchopneumonia/pneumonia Cannot rule out pneumonia Consolidation Cavitation ARDS (acute respiratory distress syndrome) Lung Infiltrate Interstitial infiltrate Lobar infiltrate Pleural Effusion Empyema Other	L. Chest X-ray – Based on radiology report only 2b. For the first abnormal chest x-ray, please check all that apply Report not available Air space density Air space opacity Bronchopneumonia/pneumonia Cannot rule out pneumonia Consolidation Cavitation ARDS (acute respiratory distress syndrome) Infiltrate (lung, interstitial, other) Lobar infiltrate Pleural Effusion Empyema Other
M1. Did the patient have any of the following new diagnoses at discharge? (Select all that apply) Acute encephalopathy/encephalitis Acute liver failure Acute myocardial infarction Acute myocarditis Acute renal failure/acute kidney injury Acute respiratory distress syndrome (ARDS) Acute respiratory failure Asthma exacerbation Bacteremia Bronchiolitis Bronchitis Chronic lung disease of prematurity/BPD Congestive heart failure COPD exacerbation Deep vein thrombosis (DVT) Diabetic ketoacidosis Disseminated intravascular coagulation (DIC) Guillain-Barre syndrome Hemophagocytic syndrome Invasive pulmonary aspergillosis Kawasaki disease Mucormycosis Multisystem inflammatory syndrome in children (MIS-C) or adults (MIS-A) Other thrombosis/embolism/coagulopathy Pneumonia Pulmonary embolism (PE) Reye’s syndrome Rhabdomyolysis Sepsis Seizures Stroke (CVA) Toxic shock syndrome (TSS)	M1. Did the patient have any of the following new diagnoses at discharge? (Select all that apply) Acute complication of sickle cell Acute encephalopathy/encephalitis Acute liver failure Acute myocardial infarction Acute myocarditis Acute renal failure/acute kidney injury Acute respiratory distress syndrome (ARDS) Acute respiratory failure Asthma exacerbation Atrial fibrillation (Afib) new-onset or paroxysmal/chronic Bacteremia Bronchiolitis Bronchitis Cardiac arrest Chronic lung disease of prematurity/BPD Congestive heart failure exacerbation COPD exacerbation Deep vein thrombosis (DVT) Diabetic ketoacidosis Disseminated intravascular coagulation (DIC) Guillain-Barre syndrome Hemophagocytic syndrome Invasive pulmonary aspergillosis Kawasaki disease Mucormycosis Multisystem inflammatory syndrome in children (MIS-C) or adults (MIS-A) Other thrombosis/embolism/coagulopathy Pneumonia Pulmonary embolism (PE) Reye’s syndrome Rhabdomyolysis Sepsis Seizures Stroke (CVA) Supraventricular tachycardia (SVT) Toxic shock syndrome (TSS) Ventricular fibrillation (Vfib) Ventricular tachycardia (V-tach)
O6a. If patient was pregnant on admission but no longer pregnant at discharge, indicate pregnancy outcome at discharge.	O6a. If patient was pregnant on admission but no longer pregnant at discharge, indicate pregnancy outcome at discharge. (If multiple fetuses, indicate outcome at discharge for each fetus in the database separately.)

2. FluSurv-NET/RSV Laboratory Survey– Attachment #7

Question on 2022-23 form	Question on 2023-24 form
4A. Select the kit name(s) (manufacturer) for the rapid influenza antigen diagnostic test performed or planned to be used at the laboratory: (Check all that apply)	5A. Select the kit name(s) (manufacturer) for the rapid influenza antigen diagnostic test performed or planned to be used at the laboratory: (Check all that apply)
5a. Select the kit name(s) (manufacturer) for all molecular assays performed or planned to be used at the laboratory: (Check all that apply)	6a. Select the kit name(s) (manufacturer) for all molecular assays performed or planned to be used at the laboratory: (Check all that apply)
5b. If more than one kit is selected above, please select the one kit name that is (or will be) used most frequently for molecular assay at the laboratory during the current influenza season:	6b. If more than one kit is selected above, please select the one kit name that is (or will be) used most frequently for molecular assay at the laboratory during the current influenza season:

HAIC

1. Multi-site Gram-Negative Surveillance Initiative (MuGSI) Case Report Form (CRF) Attachment #8

Question on original 2023 form	Question on 2024 form	Description of change
2023 Carbapenem Resistant Enterobacteriaceae (CRE)/ Carbapenem Resistant A. baumannii (CRAB) Multi-site Gram-Negative Surveillance Initiative (MuGSI) Healthcare-Associated Infections Community Interface (HAIC) Case Report	2024 Multi-site Gram-Negative Surveillance Initiative (MuGSI) Healthcare-Associated Infections Community Interface (HAIC) Case Report	Language Modification I. Updated year to 2024 II. Removed the pathogens from the updated form title since one form is used for all of MuGSI surveillance pathogens
10. Organism: ð CRE ð CRAB If CRE, select one of the following: ð Escherichia coli ð Klebsiella aerogenes ð Klebsiella oxytoca ð Enterobacter cloacae ð Klebsiella pneumoniae	10. Organism: ð Carbapenem-Resistant Enterobacterales (CRE) ð Escherichia coli ð Klebsiella pneumoniae ð Klebsiella oxytoca ð Klebsiella aerogenes ð Enterobacter cloacae ð Extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E) ð Escherichia coli ð Klebsiella pneumoniae ð Klebsiella oxytoca ð Carbapenem-Resistant A. baumannii (CRAB) ð Invasive Escherichia coli (iEC) (not CRE or ESBL-E)	Language Modification I. This is updated language to clearly delineate MuGSI pathogens and phenotypes under surveillance with the use of a one form. II. Includes the organisms/phenotypes for ESBL and iEC (from approved 2023 ESBL/iEC MuGSI CRF)
11. Incident Specimen Collection Site ð Blood ð Bone ð Bronchoalveolar lavage (CRAB only, complete Q23c) ð CSF ð Internal body site (specify):______________ ð Muscle ð Peritoneal fluid ð Pericardial fluid ð Joint/synovial fluid ð Sputum (CRAB only, complete Q23c) ð Urine ð Wound (CRAB only) (specify):______________ ð Other LRT site (CRAB only, complete Q23c) (specify):______________ ð Other normally sterile site (specify):______________	11. Specimen Collection Site(s) ð Blood ð Bone ð Bronchoalveolar lavage (CRAB only, complete Q23c) ð CSF ð Internal body site (specify):______________ ð Muscle ð Peritoneal fluid ð Pericardial fluid ð Joint/synovial fluid ð Sputum (CRAB only, complete Q23c) ð Urine (complete 22a–22c) ð Wound (CRAB only) (specify):______________ ð Other LRT site (CRAB only, complete Q23c) (specify):______________ ð Other normally sterile site (specify):______________	Language Modification I. Update to respondent instructions (i.e., when “Urine” is recorded, provide responses to Q22a–22c)
16. Patient Outcome: On the day of or in the 6 calendar days before death, was the pathogen of interest isolated from a site that meets the case definition? ð Yes ð No ð Unknown	16. Patient Outcome [Removed]	Administrative Change I. Removed the specified question from “16. Patient Outcome:” on the 2024 form. A response for this question can be calculated by CDC.
17a. Types of infection associated with culture(s): (Check all that apply) ð None ð Colonized ð Unknown ð Abscess, not skin ð AV fistula/graft infection ð Bacteremia ð Bursitis ð Catheter site infection (CVC) ð Cellulitis ð Chronic Ulcer/wound (not decubitus) ð Decubitus/pressure ulcer ð Empyema ð Endocarditis ð Epidural abscess ð Meningitis ð Osteomyelitis ð Peritonitis ð Pneumonia (CRAB cases, complete Q23c) ð Pyelonephritis ð Septic arthritis ð Septic emboli ð Septic shock ð Skin abscess ð Surgical incision infection ð Surgical site infection (internal) ð Traumatic wound ð Urinary tract infection ð Other (specify):______________	17a. Types of infection associated with culture(s): (Check all that apply) ð None ð Colonized ð Unknown ð Abscess, not skin ð AV fistula/graft infection ð Bacteremia ð Bursitis ð Catheter site infection (CVC) ð Cellulitis ð Chronic Ulcer/wound (not decubitus) ð Decubitus/pressure ulcer ð Empyema ð Endocarditis ð Epidural abscess ð Meningitis ð Osteomyelitis ð Peritonitis ð Pneumonia (CRAB cases, complete Q23c) ð Pyelonephritis (complete 22a–22c) ð Sepsis ð Urosepsis ð Septic arthritis ð Septic emboli ð Septic shock ð Skin abscess ð Surgical incision infection ð Surgical site infection (internal) ð Traumatic wound ð Urinary tract infection (complete 22a–22c) ð Other (specify):______________	Administrative Change & Language Modification I. Provided a checkbox for “Sepsis” as an infection type, including a sub-choice for “Urosepsis” II. Respondents previously entered these responses under Bacteremia or as additional notes in the comments section of the form. III. Update respondent instructions (i.e., when “Pyelonephritis” or “Urinary tract infection” are recorded, provide responses to Q22a–22c)
URINE CULTURES ONLY: [Instruction preceding Q22a–22c]	Complete questions 22a–22c for all MuGSI cases from urine cultures or where UTI or pyelonephritis is marked in question 17a:	Administrative Change & Language Modification I. This is revised language to clarify form instructions to respondents.
23b. Risk factors in the 7 days before the DISC: ð Non-invasive positive pressure ventilation (CPAP or BiPAP) at any time in the 7 calendar days before the DISC ð Nebulizer treatment at any time in the 7 calendar days before the DISC ð Mechanical ventilation at any time in the 7 calendar days before the DISC ð None	23b. Risk factors prior to CRAB DISC: ð Non-invasive positive pressure ventilation (CPAP or BiPAP) at any time in the 7 calendar days before the DISC ð Nebulizer treatment at any time in the 7 calendar days before the DISC ð Mechanical ventilation at any time in the 7 calendar days before the DISC ð None	Language Modification I. Revised and clarified the text for of the question.
Question 24 a & b come from the OMB-approved 2023 ESBL/iEC MuGSI CRF.	24a. Is antimicrobial use (IV or Oral) in the 30 days before the DISC documented? ð Yes ð No ð Unknown	Administrative Change I. This question from the OMB-approved 2023 ESBL/iEC MuGSI is consolidated to the single 2024 MuGSI CRF
Question 24 a & B come from the OMB-approved 2023 ESBL/iEC MuGSI CRF.	24b. If yes, check all antimicrobials used in the 30 days before the DISC: (Check all that apply) ð Amikacin ð Amoxicillin ð Amoxicillin/clavulanic acid ð Ampicillin ð Ampicillin/sulbactam ð Azithromycin ð Aztreonam ð Cefadroxil ð Cefazolin ð Cefdinir ð Cefepime ð Cefiderocol ð Ceixime ð Cefotaxime ð Cefoxitin ð Cefpodoxime ð Ceftaroline ð Ceftazidime ð Ceftazidime/avibactam ð Ceftizoxime ð Ceftolozane/tazobactam ð Ceftriaxone ð Cefuroxime ð Cephalexin ð Ciprofloxacin ð Clarithromycin ð Clindamycin ð Dalbavancin ð Daptomycin ð Delafloxacin ð Doripenem ð Doxycycline ð Eravacycline ð Ertapenem ð Fidaxomicin ð Fosfomycin ð Gentamicin ð Imipenem/cilastatin ð Levofloxacin ð Linezolid ð Meropenem ð Meropenem/vaborbactam ð Metronidazole ð Moxifloxacin ð Nitrofurantoin ð Omadacycline ð Oritavancin ð Penicillin ð Piperacillin/tazobactam ð Polymyxin B ð Polymyxin E (colistin) ð Rifaximin ð Tedizolid ð Telavancin ð Tigecycline ð Tobramycin ð Trimethoprim ð Trimethoprim/sulfamethoxazole ð Vancomycin ð IV ð PO ð Other (specify):___________ ð Other (specify):___________ Reminder: Any prior antimicrobial use that is not noted above should be documented in the other (specify) field.	Administrative Change I. As noted for 24a, this question from the OMB-approved 2023 ESBL/iEC MuGSI is consolidated to the single 2024 MuGSI CRF
24c. COVID-Net Case ID:_________	25c. COVID-Net Case ID in the year before or day of DISC:_________ ð None or N/A	Language Modification & Administrative Change I. Updated the question number II. Added language to state the specified timeframe III. Included a checkbox for “None or N/A” to differentiate from missing data
28. Susceptibility Results Please complete the table below based on the information found in the indicate data source	29. Susceptibility Results Please complete the table below based on the information found in the indicate data source ð No susceptibility data from the medical record are available	Administrative Change I. Updated the question number II. Included a checkbox for “No susceptibility data form the medical record are available” to differentiate from missing data

2. Multi-site Gram-Negative Surveillance Initiative (MuGSI) Community-Associated Carbapenemase-Producing Carbapenem-Resistant Enterobacterales (CA CP-CRE) Health interview - Attachment #9

Original Instruction	Proposed Change to Instruction
[If answer to Q22 = 1, i.e., interviewee lives alone, skip to Section G]	[If answer to Q22 = 1, i.e., interviewee lives alone, skip to Section 9]

2. Invasive Staphylococcus aureus Infection Case Report - Attachment #10

2023 CRF Question	Changes to the 2024 CRF Question
	15a. Is the isolate MRSA or MSSA? □ MRSA □ MSSA □ Unknown [new question]
34a. COVID-NET CASE ID: ________________	34a. COVID-NET CASE ID in the year before or day of the DISC: ________________ □ None or N/A [updated language, added checkbox]

2. Clostridiodies difficile Infection (CDI) Case Report and Treatment Form - Attachment #11

2023 CRF	2024 CRF	Changes
9a. EIA Positive Negative Not tested	9a. EIA Positive Negative Not tested Unknown	Added option for “unknown”
9b. GDH Positive Negative Not tested	9b. GDH Positive Negative Not tested Unknown	Added option for “unknown”
9c. Cytotoxin Positive Negative Not tested	9c. Cytotoxin Positive Negative Not tested Unknown	Added option for “unknown”
9d. NAAT (C. diff only) Positive Negative Not tested	9d. NAAT (C. diff only) Positive Negative Not tested Unknown	Added option for “unknown”
9e. NAAT (GI panel) Positive Negative Not tested	9e. NAAT (GI panel) Positive Negative Not tested Unknown	Added option for “unknown”
9f. Other (specify) Positive Negative Not tested	9f. Other (specify) Positive Negative Not tested Unknown	Added option for “unknown”
21. Underlying conditions Transplant, solid organ	21. Underlying conditions Transplant, solid organ: ____________________	Added a field to specify organ transplanted
34f.1 If YES, which medication was taken	34f.1 If YES, which treatment was taken?	Changed “medication” to “treatment”
37. COVID-NET Case IDs: ________	37. COVID-NET Case IDs in the year before or day of DISC: _________ None or N/A	Clarified the time period of the question Added a checkbox for “none or N/A”

2. Clostridiodies difficile Infection (CDI) Annual Surveillance Officers Survey - Attachment #12

Existing question	Modified question
2. In 2022, did any laboratories drop out of participation?	2. In 2023, did any laboratories drop out of participation? (changed year to 2023 to reflect change in survey year)
3. In 2022, did you identify any additional laboratories inside or outside of your catchment area which identify C.diff assays from persons who are residents of your catchment area?	3. In 2023, did you identify any additional laboratories inside or outside of your catchment area which identify C.diff assays from persons who are residents of your catchment area? (changed year to 2023 to reflect change in survey year)
10. Did your site complete a physician/outpatient provider survey in 2022?	10. Did your site complete a physician/outpatient provider survey in 2023? (changed year to 2023 to reflect change in survey year)
13. For each facility that treated a case in 2022, please provide the following	13. For each facility that treated a case in 2023, please provide the following (changed year to 2023 to reflect change in survey year)

2. Annual Survey of Laboratory Testing Practices for C. difficile Infections - Attachment #13

Existing question	Modified question
Was this a new laboratory in 2022?	Was this a new laboratory in 2023?
How often did you receive line lists from this lab in 2022?	How often did you receive line lists from this lab in 2023?
How did you receive line lists from this lab in 2022?	How did you receive line lists from this lab in 2023?
Did you receive specimens from this lab in 2022?	Did you receive specimens from this lab in 2023?
Was this lab audited in 2022?	Was this lab audited in 2023?
Types of facilities in your catchment area served by this lab in 2022	Types of facilities in your catchment area served by this lab in 2023
Did your laboratory ever send specimens off-site for Clostridioides difficile testing in 2022?	Did your laboratory ever send specimens off-site for Clostridioides difficile testing in 2023?
2a. Which testing method(s) for Clostridioides difficile (C. difficile) did your laboratory perform in 2022?	2a. Which testing method(s) for Clostridioides difficile (C. difficile) did your laboratory perform in 2023?
Did your laboratory use this testing method for Clostridioides difficile (C. difficile) in 2022?	Did your laboratory use this testing method for Clostridioides difficile (C. difficile) in 2023?
Did you use this testing method in this way for all of 2022?	Did you use this testing method in this way for all of 2023?
3a. Which EIA test kit was used by your laboratory in 2022?	3a. Which EIA test kit was used by your laboratory in 2023?
3b. Which Nucleic Acid Amplification test was used by your laboratory in 2022?	3b. Which Nucleic Acid Amplification test was used by your laboratory in 2023?
4a. If your laboratory used a multiplexed molecular diagnostic (e.g., Biofire Filmarray GI Panel, Luminex xTAG GPP) to test for several GI pathogens in 2022, did your laboratory suppress the C. difficile result so that clinicians could not see it?	4a. If your laboratory used a multiplexed molecular diagnostic (e.g., Biofire Filmarray GI Panel, Luminex xTAG GPP) to test for several GI pathogens in 2023, did your laboratory suppress the C. difficile result so that clinicians could not see it?
4b. If your laboratory used a multiplexed diagnostic in 2022 and the result was suppressed, where does the suppression occur?	4b. If your laboratory used a multiplexed diagnostic in 2023 and the result was suppressed, where does the suppression occur?
5a. If your laboratory used a nucleic acid amplification test (NAAT) (e.g., Cepheid Xpert C. difficile) as first line testing followed by a toxin EIA test (whenever NAAT result is positive) in 2022, did your laboratory suppress the positive NAAT result so that clinicians could not see it?	5a. If your laboratory used a nucleic acid amplification test (NAAT) (e.g., Cepheid Xpert C. difficile) as first line testing followed by a toxin EIA test (whenever NAAT result is positive) in 2023, did your laboratory suppress the positive NAAT result so that clinicians could not see it?
5b. If your laboratory used NAAT as first line testing followed by confirmatory toxin EIA testing in 2022, and both the NAAT and toxin EIA results were released to the clinician, did your laboratory provide any comments to help the clinician interpret the test results (e.g., NAAT-positive only result might represent colonization, etc.)?	5b. If your laboratory used NAAT as first line testing followed by confirmatory toxin EIA testing in 2023, and both the NAAT and toxin EIA results were released to the clinician, did your laboratory provide any comments to help the clinician interpret the test results (e.g., NAAT-positive only result might represent colonization, etc.)?
6. What are the LOINC or internal testing codes associated with the tests your lab used in 2022 (e.g. LOINC codes 13957-6, 34713-8, or 54067-4)?	6. What are the LOINC or internal testing codes associated with the tests your lab used in 2023 (e.g. LOINC codes 13957-6, 34713-8, or 54067-4)?
7. Did your lab have a policy to reject stool specimens for C. difficile testing in 2022?	7. Did your lab have a policy to reject stool specimens for C. difficile testing in 2023?
7a. Did your rejection policy for stool specimens change between January 1, 2022 and December 31, 2022?	7a. Did your rejection policy for stool specimens change between January 1, 2023 and December 31, 2023?
8. How many stool samples did you test for C. difficile each month in 2022?	8. How many stool samples did you test for C. difficile each month in 2023?

2. HAIC Candidemia Case Report - Attachment #14

2023 CRF Question	2024 CRF Question
CANDIDEMIA 2023 CASE REPORT FORM (header)	CANDIDEMIA 2024 CASE REPORT FORM (header) (changed year)
Version: Short Form 2023, Last Updated: 07/29/2022 (footnotes)	Version: Short Form 2024, Last Updated: 07/29/2023 (footnotes) (changed year and date)
23. Candida species from initial positive blood culture (check all that apply): Candida albicans (CA) Candida glabrata (CG) Candida parapsilosis (CP) Candida tropicalis (CT) Candida dubliniensis (CD) Candida lusitaniae (CL) Candida krusei (CK) Candida guilliermondii (CGM) Candida, other (CO) specify: ______________ Candida, germ tube negative/non albicans (CGN) Candida species (CS) Pending	23. Candida species from initial positive blood culture (check all that apply): Candida albicans (CA) Candida auris (CAU) Candida glabrata (CG) Candida parapsilosis (CP) Candida tropicalis (CT) Candida dubliniensis (CD) Candida lusitaniae (CL) Candida krusei (CK) Candida guilliermondii (CGM) Candida, other (CO) specify: ______________ Candida, germ tube negative/non albicans (CGN) Candida species (CS) Pending (added new response option)
24. Antifungal susceptibility testing Species CA CG CP CT CD CL CK CGM CO CGN CS Pending	24. Antifungal susceptibility testing Species CA CAU CG CP CT CD CL CK CGM CO CGN CS Pending (added new response option)
25. Did the patient have a culture-independent diagnostic test (CIDT) for Candida, (e.g., T2), on the day of or in the 6 days before the DISC? 1 Yes 0 No 9 Unknown	25. Did the patient have a PCR molecular test for Candida (e.g., T2) in the 6 days before or two days after the DISC? 1 Yes 0 No 9 Unknown (changed question wording)
26a. If yes, provide dates of all subsequent positive Candida blood cultures and select the species: Date Drawn (mm-dd-yyyy) ___ ___ - ___ ___ - ___ ___ ___ ___ Species identified* CA CG CP CT CD CL CK CGM CO:_________ CGN CS Pending	26a. If yes, provide dates of all subsequent positive Candida blood cultures and select the species: Date Drawn (mm-dd-yyyy) ___ ___ - ___ ___ - ___ ___ ___ ___ Species identified* CA CAU CG CP CT CD CL CK CGM CO:_________ CGN CS Pending (added new response option)
40. Underlying conditions (Check all that apply): Chronic Lung Disease Cystic Fibrosis Chronic Pulmonary disease Chronic Metabolic Disease Diabetes Mellitus With Chronic Complications Cardiovascular Disease CVA/Stroke/TIA Congenital Heart disease Congestive Heart Failure Myocardial infarction Peripheral Vascular Disease (PVD) Gastrointestinal Disease Diverticular disease Inflammatory Bowel Disease Peptic Ulcer Disease Short gut syndrome Immunocompromised Condition HIV infection AIDS/CD4 count <200 Primary Immunodeficiency Transplant, Hematopoietic Stem Cell Transplant, Solid Organ	40. Underlying conditions (Check all that apply): Chronic Lung Disease Cystic Fibrosis Chronic Pulmonary disease Chronic Metabolic Disease Diabetes Mellitus With Chronic Complications Cardiovascular Disease CVA/Stroke/TIA Congenital Heart disease Congestive Heart Failure Myocardial infarction Peripheral Vascular Disease (PVD) Gastrointestinal Disease Diverticular disease Inflammatory Bowel Disease Peptic Ulcer Disease Short gut syndrome Immunocompromised Condition HIV infection AIDS/CD4 count <200 Primary Immunodeficiency Transplant, Hematopoietic Stem Cell Transplant, Solid Organ (specify): ________ (added new response option)
52. Did the patient have a CVC in the 2 calendar days before, not including the DISC? 1 Yes 2 No 3 Had CVC but can’t find dates 9 Unknown If yes, check here if central line in place for > 2 calendar days:	52. Did the patient have a CVC in the 2 calendar days before, not including the DISC? 1 Yes 2 No 3 Had CVC but can’t find dates 9 Unknown If yes, was the central line in place for > 2 calendar days: 1 Yes 0 No 9 Unknown (changed question wording, added additional response options)
55b. If yes, EIP COVID-NET Case ID: ____________ 9 Unknown Out of EIP COVID-NET catchment area	55b. If yes, EIP COVID-NET Case ID: ____________ None or N/A (added new response option)
AFST results for additional Candida isolates Species CA CG CP CT CD CL CK CGM CO CGN CS Pending	AFST results for additional Candida isolates Species CA CAU CG CP CT CD CL CK CGM CO CGN CS Pending (added new response option)

2. Laboratory Testing Practices for Candidemia Questionnaire - Attachment #15

2023 Lab Survey Question	2024 Lab Survey Question
2023 LABORATORY TESTING PRACTICES FOR CANDIDEMIA QUESTIONNAIRE (header)	2024 LABORATORY TESTING PRACTICES FOR CANDIDEMIA QUESTIONNAIRE (header) (changed year)
2023 Page # of # (footnotes)	2024 Page # of # (footnotes) (changed year)
Does this laboratory employ culture-independent diagnostic tests (CIDTs) to identify Candida from blood specimens? Yes (got to Q14) No (got to Q17) Unknown	Does this laboratory employ PCR molecular tests to identify Candida from blood specimens? Yes (go to Q14) No (go to Q17) Unknown (changed question wording)
Does this laboratory employ any other CIDTs to identify Candida from blood specimens? Yes (specify) _____________ No Unknown Not applicable	Does this laboratory employ any other PCR molecular tests to identify Candida from blood specimens? Yes (specify) _____________ No Unknown Not applicable (changed question wording)
17) If No for Question 13, does this laboratory have plans to employ culture independent diagnostics for Candida identification in the near future (e.g., T2Candida Panel, BioFire)? Yes No Unknown Not applicable	17) If No for Question 13, does this laboratory have plans to employ PCR molecular tests for Candida identification in the near future (e.g., T2Candida Panel, BioFire)? Yes No Unknown Not applicable (changed question wording)